My research group primarily focuses on investigating the regulatory mechanisms of metabolic reprogramming and post-translational modifications in the development and progression of malignant tumors. By integrating multi-omics proteomics, metabolomics, tumor biology, gene-editing technologies, and high-throughput screening, along with clinical samples, tumor organoids, and animal models, my group aims to uncover key metabolic and signaling pathways involved in tumorigenesis. The ultimate goal is to identify novel therapeutic targets and develop innovative strategies for cancer treatment.

In recent years, my research has primarily focused on investigating the mechanisms underlying cancer development and progression, as well as drug development for cancer prevention and treatment. My research findings have been published as first author in Cell and Nature, and as corresponding author in internationally renowned journals such as Journal of Experimental Medicine, EMBO Journal, Nature Communications (2024, 2025), Trends in Cell Biology, and Advanced Science. Key scientific contributions include:

(1) Elucidating the molecular mechanisms by which palmitoylation modifications of the G protein-coupled receptor MC1R and glutathione peroxidase GPX4 regulate the development and progression of malignant tumors (Nature, 2017; Cancer Research, 2023; Nature Communications, 2025);

(2) Revealing common signaling pathways essential for the development of RAS/RAF mutant tumors (Cell, 2019; Nature Communications, 2024; Journal of Experimental Medicine, 2025);

(3) Uncovering and exploring the molecular mechanisms by which metabolic pathways regulate ferroptosis, providing new targets for the development of metabolism-targeted cancer treatment strategies (Advanced Science, 2023; Trends in Cell Biology, 2024; EMBO Journal, 2025).

2021 National High-Level Young Talent

2020 Shenzhen Overseas High-Level Talent

2020 NIH K99/R00 Pathway to Independence Award

2016 American Association for Cancer Research Scholar-in-Training Award

1. SLC25A1 and ACLY maintain cytosolic acetyl-CoA to regulate ferroptosis susceptibility via FSP1 acetylation. EMBO Journal. Li, W.#, Han, J.#, Huang, B. #, Xu, T. #, Wan, Y., Luo, D., Kong, W., Yu, Y., Zhang, L., Nian, Y. *, Chu, B. *, Yin, C. * 2025, https://doi.org/10.1038/s44318-025-00369-5

2. PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers. Journal of Experimental Medicine. He, Y.#, Li, W.#, Zhang, M. #, Wang, H., Lin, P., Yu, Y., Huang, B., Hao, M., He, J., Kong, W., Luo, D., Xu, T., Wang, J., Huang, Y., Zhao, Q., Liu, Y., Zhang, J., Nian, Y., Zhang, L., Zhu, B., Yin, C.* 2025/01. 222(3): e20241147.

3. Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis. Nature Communications. Huang, B.#, Wang, H.#, Liu, S.#, Hao, M.#, Luo, D., Zhou, Y., Huang, Y., Nian, Y., Zhang, L., Chu, B., Yin, C.* 2025/01. 16: 867. DOI:10.1038/s41467-025-56344-5

4. Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma. Nature Communications. Wen, Y.#, Wang, H.#, Yang, X.#, Zhu, Y., Li, M., Ma, X., Huang, L., Wan, R., Zhang, C., Li, S., Jia, H., Guo, Q., Lu, X., Li, Z., Shen, X., Zhang, Q.*, Si, L.*, Yin, C.*, Liu, T*. 2024/11. 15, 10088.

5. Gut microbial metabolism in ferroptosis and colorectal cancer. Trends in Cell Biology. Cui, W.#, Hao, M.#, Yang, X.*, Yin, C.*, Chu, B*. 2024/08. 10(11)

6. Tryptophan metabolism acts as a new anti-ferroptotic pathway to mediate tumor growth. Advanced Science. Liu, D.#, Liang, C.#, Huang, B.#, Zhuang, X., Cui, W., Yang, L., Yang, Y., Zhang, Y., Fu, X., Zhang, X., Du, L., Gu, W., Wang, X., Yin, C.*, Chai, R.*, Chu, B.* 2023/02. 10(6), 2204006.

7. Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis. Clinical Immunology. Liu, L. #, Zhou, Y. #, Luo, D. #, Sun, X., Li, H., Lu, Y., Wang, J., Zhang, M., Lin, N., Yin, C.*, Li, X.*, 2023/01. 252023

8. AMPK phosphorylates ZDHHC13 to increase MC1R activity and suppress melanomagenesis. Cancer Research. Sun, Y.#, Li, X.#, Yin, C.#, Zhang, J., Liang, E., Wu, X., Ni, Y., Arbesman, J., Goding, C. R., Chen, S. 2023/01. 83 (7): 1062–1073.

9. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. Cell. Yin, C.#, Zhu, B.#, Zhang, T.#, Liu, T.#, Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., Zhang, J., Li, L., Wei, G., Xu, Z., Gao, X., Huang, C., Wei, Z., Goding, C. R., Wang, P.*, Deng, X.*, Cui, R.* 2019/02. 176(5), 1113-1127.

10. Palmitoylation-dependent activation of MC1R prevents melanomagenesis. Nature. Chen, S.#, Zhu, B.#, Yin, C.#, Liu, W., Han, C., Chen, B., Liu, T., Li, X., Chen, X., Li, C., Hu, L., Zhou, J., Xu, Z., Gao, X., Wu, X., Goding, C. R., Cui, R. 2017/09. 549(7672), 399-403.